...
首页> 外文期刊>Andrology >Revisiting oestrogen antagonists (clomiphene or tamoxifen) as medical empiric therapy for idiopathic male infertility: a meta-analysis
【24h】

Revisiting oestrogen antagonists (clomiphene or tamoxifen) as medical empiric therapy for idiopathic male infertility: a meta-analysis

机译:回顾雌激素拮抗剂(克罗米芬或他莫昔芬)作为特发性男性不育症的医学经验疗法:一项荟萃分析

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

The aim of this study was to synthesize and present the latest available evidence regarding the use of oestrogen antagonists as empiric medical therapy for idiopathic male infertility with oligo and/or asthenoteratozoospermia through meta-analysis of randomized controlled trials (RCTs). Systematic literature acquisition was done for English and other foreign language biomedical databases up to March, 2013. RCTs relevant to the topic were identified and critically appraised independently by two physician reviewers. Dichotomous data of pregnancy rate and adverse events were extracted for calculation of odds ratio (OR) and 95% confidence interval (CI). Effect estimates were pooled using Peto method with fixed effect model. The continuous data of semen and endocrine parameters were calculated for the mean difference between pre-and post-treatment effects, the weighted mean difference (WMD) and SD between the control and intervention group were determined and pooled using the random effects model. Inter-study heterogeneity and publication bias were assessed. The Preferred Reporting Items for Systematic Reviews and Meta-Analyses guideline for meta-analysis reporting was followed. Eleven RCTs of good methodological quality were included for meta-analysis. The pooled effect estimates showed that oestrogen antagonists use was associated with a statistically significant increased pregnancy rate compared with controls (pooled OR 2.42; 95% CI 1.47-3.94; p = 0.0004). Significant increase in sperm concentration (WMD 5.24; 95% CI 2.12, 88.37; p = 0.001) and per cent sperm motility (WMD 4.55; 95% CI 0.73, 8.37; p = 0.03) were also noted. While significant elevation of serum follicle stimulating hormone (WMD 4.19 95% CI 2.05, 6.34; p = 0.0001) and testosterone (WMD 54.59; 95% CI 15.92, 93.27; p = 0.006) was associated with its use. No significant difference in adverse event was noted between oestrogen antagonists-treated group and controls. The evidence suggests that oestrogen antagonists as empiric medical therapy for idiopathic male infertility with low non-serious adverse event associated, may increase spontaneous pregnancy rate, improve sperm concentration and per cent sperm motility.
机译:这项研究的目的是通过对随机对照试验(RCT)进行荟萃分析,综合并提供有关雌激素拮抗剂作为特发性男性不育症伴有寡聚和/或非小动脉无精子症的经验医学治疗方法的最新证据。截止到2013年3月,系统地获取了英语和其他外语生物医学数据库的文献。与该主题相关的RCT被两名医师审阅者独立鉴定和严格评估。提取妊娠率和不良事件的二分数据,以计算比值比(OR)和95%置信区间(CI)。使用具有固定效果模型的Peto方法汇总效果估计。计算治疗前后效果的平均差异的精液和内分泌参数的连续数据,确定对照组和干预组之间的加权平均差异(WMD)和SD,并使用随机效应模型进行汇总。评估了研究间的异质性和发表偏见。遵循了荟萃分析报告的系统评价和荟萃分析首选报告项目指南。包括11项方法学质量良好的RCT进行荟萃分析。汇总的影响评估表明,与对照组相比,雌激素拮抗剂的使用与统计学上显着增加的妊娠率相关(合并OR 2.42; 95%CI 1.47-3.94; p = 0.0004)。还注意到精子浓度显着增加(WMD 5.24; 95%CI 2.12,88.37; p = 0.001)和精子活力百分比(WMD 4.55; 95%CI 0.73,8.37; p = 0.03)。血清卵泡刺激素(WMD 4.19 95%CI 2.05,6.34; p = 0.0001)和睾丸激素(WMD 54.59; 95%CI 15.92,93.27; p = 0.006)显着升高与其使用有关。雌激素拮抗剂治疗组与对照组之间的不良事件无明显差异。有证据表明,雌激素拮抗剂作为特发性男性不育症的经验性药物疗法,伴有较低的非严重不良事件,可能增加自发妊娠率,提高精子浓度和精子活动率。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号